C4 Therapeutics (CCCC) Treasury Shares (2019 - 2026)

C4 Therapeutics' Treasury Shares history runs 7 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Treasury Shares changed N/A year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $1.5 million, up 100.65% from the prior year.
• Treasury Shares rose to $4.5 million in Q1 2026 per CCCC's latest filing, from $2.9 million in the prior quarter.
• Across five years, Treasury Shares topped out at $4.5 million in Q1 2026 and bottomed at $465291.0 in Q4 2022.
• The 5-year median for Treasury Shares is $735865.0 (2023), against an average of $1.4 million.
• Across the five-year window, Treasury Shares gained 28.04% in 2023 and soared 100.65% in 2024, its largest moves.
• Year by year, Treasury Shares stood at $465291.0 in 2022, then jumped by 61.23% to $750210.0 in 2023, then jumped by 100.65% to $1.5 million in 2024, then jumped by 90.76% to $2.9 million in 2025, then soared by 55.57% to $4.5 million in 2026.
• Per Business Quant, the three latest CCCC Treasury Shares figures stand at $4.5 million (Q1 2026), $2.9 million (Q3 2025), and $3.0 million (Q2 2025).